Here are four things to know:
1. IBSchek is a blood test that identifies the presence of two antibodies, anti-CdtB and anti-vinculin, which are indicative of diarrhea-predominant IBS and mixed-type IBS.
2. These key biomarkers are now included in the Rome Foundation’s official Rome IV Clinical Decision Toolkit. The Rome Foundation is an independent nonprofit organization that aims to improve the lives of people with functional gastrointestinal disorders.
3. CDI is continuing to establish new commercial partnerships and distribution networks to expand IBSchek in the U.S.
4. CDI is also expanding their test menu to include a serum-based ELISA test panel for celiac disease; celiac and IBS patients have similar symptoms, especially IBS-D and IBS-M patients. CDI will begin accepting diagnostic samples for celiac testing in June 2018.
More articles on gastroenterology:
FDA expands Tofacitinib indication for ulcerative colitis: 5 notes
3 insights into Fujifilm’s soon-to-debut endoscope
Marshall Health, Kansas City VA Medical Center & more: 3 GI practices in the news
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
